This Drug Could be Effective Against Tumors with a Rare Mutation
According to a story from Medscape, in a recent study the drug capivasertib appeared to be effective as a treatment for certain metastatic cancer tumors. Classified as an inhibitor of…
According to a story from Medscape, in a recent study the drug capivasertib appeared to be effective as a treatment for certain metastatic cancer tumors. Classified as an inhibitor of…
According to ANCA Vasculitis News, the FDA recently approved Riabni (rituximab-arrx) for the treatment of adult patients with two specific subtypes of ANCA vasculitis: microscopic polyangiitis (MPA) and granulomatosis with…
In early January 2021, biopharmaceutical company BlueRock Therapeutics ("BlueRock"), in collaboration with the Memorial Sloan Kettering Cancer Center, announced via press release that its Investigational New Drug (IND) application for…
According to a story from Globe Newswire, the genetic medicine company Sarepta Therapeutics has announced top-line data from part one of its clinical trial. This trial is investigating its experimental…
When you think of malaria, are mosquitos the first image that appears? While a microscopic parasite, Plasmodium falciparum, is responsible for malaria, mosquitos are often the vectors, carrying and transmitting…
The statistics are grim. A survey of 12,000 US nursing homes finds over 56,000 COVID related deaths as of July 2020. This number represents ten percent of all cases in…
Veer Basal, age 14, first started showing signs of Friedreich's ataxia when he was around ten years old. The first sign that something was wrong was when Veer began to…
In a recent press release, biopharmaceutical company Ultragenyx Pharmaceutical Inc. ("Ultragenyx") shared positive safety and efficacy data from Phase 1/2 clinical trials on gene therapy solutions for ornithine transcarbamylase…
In a press release from early January 2021, genetic medicines company Generation Bio Co. ("Generation Bio") announced data from a variety of studies. In one, the company shared that…